BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Sold by Moody Aldrich Partners LLC

Moody Aldrich Partners LLC lessened its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 19.3% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 99,684 shares of the company's stock after selling 23,825 shares during the period. Moody Aldrich Partners LLC owned approximately 0.05% of BridgeBio Pharma worth $2,735,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC raised its stake in shares of BridgeBio Pharma by 17.7% in the third quarter. Allspring Global Investments Holdings LLC now owns 5,322 shares of the company's stock valued at $135,000 after acquiring an additional 801 shares during the period. Amalgamated Bank raised its position in BridgeBio Pharma by 24.7% in the 2nd quarter. Amalgamated Bank now owns 4,863 shares of the company's stock worth $123,000 after purchasing an additional 962 shares during the period. Diversified Trust Co lifted its stake in BridgeBio Pharma by 3.0% in the third quarter. Diversified Trust Co now owns 36,772 shares of the company's stock worth $936,000 after purchasing an additional 1,059 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of BridgeBio Pharma by 21.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,801 shares of the company's stock valued at $170,000 after buying an additional 1,214 shares during the period. Finally, Quarry LP grew its stake in shares of BridgeBio Pharma by 27.1% during the second quarter. Quarry LP now owns 7,500 shares of the company's stock valued at $190,000 after buying an additional 1,600 shares during the last quarter. 99.85% of the stock is currently owned by institutional investors.

BridgeBio Pharma Stock Performance

NASDAQ:BBIO traded down $1.76 during trading hours on Friday, reaching $34.21. The company's stock had a trading volume of 3,032,037 shares, compared to its average volume of 2,647,242. The company has a market capitalization of $6.47 billion, a P/E ratio of -14.19 and a beta of 1.05. The stock has a 50 day moving average price of $30.11 and a two-hundred day moving average price of $27.21. BridgeBio Pharma, Inc. has a 12 month low of $21.62 and a 12 month high of $41.04.

Insider Transactions at BridgeBio Pharma

In other news, CEO Neil Kumar sold 27,389 shares of the company's stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $22.41, for a total transaction of $613,787.49. Following the transaction, the chief executive officer now directly owns 4,897,443 shares of the company's stock, valued at approximately $109,751,697.63. This represents a 0.56 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Global Investors Lp Viking sold 3,065,616 shares of the stock in a transaction on Friday, January 31st. The shares were sold at an average price of $34.90, for a total value of $106,989,998.40. Following the sale, the insider now owns 22,055,375 shares of the company's stock, valued at approximately $769,732,587.50. This represents a 12.20 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 3,492,093 shares of company stock valued at $122,029,004. Corporate insiders own 24.66% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on BBIO shares. HC Wainwright reissued a "buy" rating and set a $49.00 price target on shares of BridgeBio Pharma in a research note on Monday, December 16th. Evercore ISI lifted their target price on BridgeBio Pharma from $45.00 to $50.00 and gave the stock an "outperform" rating in a research report on Monday, December 23rd. Bank of America upped their price target on shares of BridgeBio Pharma from $42.00 to $45.00 and gave the stock a "buy" rating in a report on Monday, November 25th. Scotiabank lifted their price objective on shares of BridgeBio Pharma from $45.00 to $48.00 and gave the company a "sector outperform" rating in a report on Monday, November 25th. Finally, Leerink Partners dropped their target price on shares of BridgeBio Pharma from $47.00 to $46.00 and set an "outperform" rating on the stock in a research note on Thursday, October 17th. One analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $49.00.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.